ATE198891T1 - Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems - Google Patents

Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems

Info

Publication number
ATE198891T1
ATE198891T1 AT93304102T AT93304102T ATE198891T1 AT E198891 T1 ATE198891 T1 AT E198891T1 AT 93304102 T AT93304102 T AT 93304102T AT 93304102 T AT93304102 T AT 93304102T AT E198891 T1 ATE198891 T1 AT E198891T1
Authority
AT
Austria
Prior art keywords
treatment
nervous system
central nervous
system disorders
alkyl
Prior art date
Application number
AT93304102T
Other languages
German (de)
English (en)
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE198891T1 publication Critical patent/ATE198891T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93304102T 1992-05-29 1993-05-26 Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems ATE198891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ATE198891T1 true ATE198891T1 (de) 2001-02-15

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93304102T ATE198891T1 (de) 1992-05-29 1993-05-26 Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems

Country Status (21)

Country Link
EP (1) EP0582368B1 (enExample)
JP (1) JP3219541B2 (enExample)
CN (1) CN1043994C (enExample)
AT (1) ATE198891T1 (enExample)
AU (1) AU668159B2 (enExample)
CA (1) CA2097016A1 (enExample)
CZ (1) CZ282783B6 (enExample)
DE (1) DE69329887T2 (enExample)
DK (1) DK0582368T3 (enExample)
ES (1) ES2153373T3 (enExample)
FI (1) FI101538B1 (enExample)
GR (1) GR3035587T3 (enExample)
HU (1) HU218278B (enExample)
IL (1) IL105827A (enExample)
MX (1) MX9303124A (enExample)
MY (1) MY109943A (enExample)
NO (1) NO305125B1 (enExample)
NZ (1) NZ247703A (enExample)
PT (1) PT582368E (enExample)
RU (1) RU2125574C1 (enExample)
TW (1) TW268005B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
PL329217A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Pain relieving method
BR9708145A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Processo para tratamento de dor de enxaqueca
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
AU720366B2 (en) * 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CA2882560C (en) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of risperidone and paliperidone for use in immunoassays
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
PL2888373T3 (pl) 2012-08-21 2018-08-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
ES3057437T3 (en) 2012-08-21 2026-03-02 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof
ES2701062T3 (es) * 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
CN108368180B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (enExample) * 1972-04-04 1975-11-28 Wander Ag Dr A
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
SE7610219L (sv) * 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
CH624682A5 (enExample) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
IL105827A0 (en) 1993-09-22
CZ102493A3 (en) 1993-12-15
MY109943A (en) 1997-10-31
IL105827A (en) 1997-02-18
DK0582368T3 (da) 2001-02-05
CN1043994C (zh) 1999-07-07
DE69329887D1 (de) 2001-03-01
JP3219541B2 (ja) 2001-10-15
FI101538B (fi) 1998-07-15
NO931917D0 (no) 1993-05-26
FI101538B1 (fi) 1998-07-15
CA2097016A1 (en) 1993-11-30
HU9301579D0 (en) 1993-09-28
HU218278B (en) 2000-07-28
CN1085903A (zh) 1994-04-27
PT582368E (pt) 2001-05-31
NO931917L (no) 1993-11-30
TW268005B (enExample) 1996-01-11
CZ282783B6 (cs) 1997-10-15
JPH0687862A (ja) 1994-03-29
NO305125B1 (no) 1999-04-06
FI932445A0 (fi) 1993-05-28
FI932445L (fi) 1993-11-30
ES2153373T3 (es) 2001-03-01
EP0582368B1 (en) 2001-01-24
HUT66180A (en) 1994-09-28
DE69329887T2 (de) 2001-05-23
EP0582368A1 (en) 1994-02-09
AU668159B2 (en) 1996-04-26
MX9303124A (es) 1993-11-01
GR3035587T3 (en) 2001-06-29
NZ247703A (en) 1995-07-26
AU3980793A (en) 1993-12-02
RU2125574C1 (ru) 1999-01-27

Similar Documents

Publication Publication Date Title
DE69329887D1 (de) Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
GB8823731D0 (en) Biologically active compounds
ES2164718T3 (es) Compuestos triciclicos de amida y urea utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
MX9200015A (es) Derivados de amida y proceso para su preparacion.
DE69411424D1 (de) Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
NO1998008I1 (no) Naratriptan
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
FI821598A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-alkyl-2-aminotetralinderivat
FI893751A0 (fi) Kemiska foereningar.
ATE88894T1 (de) Methode zur behandlung von kachexie und bestimmte dafuer anzuwendende verbindungen.
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
MA21902A1 (fr) Procede pour la preparation de peptitides hemoregulateurs et des compositions pharmaceutiques les comtenant .
ATE69049T1 (de) Chinazolin-derivat, verfahren zu dessen herstellung und mittel zur behandlung von cerebraler disfunktion als aktiver inhaltsstoff.
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
ATE152708T1 (de) (1,2n) und (3,2n)-karbozyklische-2-amino- tetralinderivate
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ES2097188T3 (es) Derivados organosilanos, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen
ES2037825T3 (es) Uso farmaceutico de tioeteres aromaticos.
ES2133095A1 (es) Acidos alquilidenglutaminicos con propiedades farmaceuticas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee